Live Breaking News & Updates on Master translational research services agreement

Stay updated with breaking news from Master translational research services agreement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Final Results for the Year Ended 31 December 2021

Investegate announcements from Hemogenyx Pharma Plc, Final Results for the Year Ended 31 December 2021 ....

Milmort , Waals-gewest , Belgium , Manhattanville , New-york , United-states , Wuxi , Jiangsu , China , United-kingdom , Delaware , Dover

Verismo Therapeutics, Inc., Enters into Master Translational Research Services Agreement with the University of Pennsylvania

/PRNewswire/ Verismo Therapeutics, Inc., a recent University of Pennsylvania spinout researching and developing a novel multichain KIR-CAR platform. ....

University-of-pennsylvania , Pennsylvania , United-states , Philadelphia , Bryan-kim , Alyson-kuritz , University-of-pennsylvania-penn , Penn-perelman-school-of-medicine , Master-translational-research-services-agreement , Perelman-school-of-medicine , Verismo-therapeutics-inc , Verismo-therapeutics

Verismo Therapeutics, Inc., Enters into Master Translational Research Services Agreement with the University of Pennsylvania

/PRNewswire/ Verismo Therapeutics, Inc., a recent University of Pennsylvania spinout researching and developing a novel multichain KIR-CAR platform. ....

University-of-pennsylvania , Pennsylvania , United-states , Philadelphia , Bryan-kim , Alyson-kuritz , University-of-pennsylvania-penn , Penn-perelman-school-of-medicine , Master-translational-research-services-agreement , Perelman-school-of-medicine , Verismo-therapeutics-inc , Verismo-therapeutics

Investegate |Hemogenyx Pharma Plc Announcements | Hemogenyx Pharma Plc: Final Results

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.

• Demonstrated that HEMO-CAR-T cells are effective against Acute Myloid Leukemia in vitro and in vivo
• Developed a
novel cell-based platform technology, referred to as CBR, for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer ....

New-york , United-states , Cornell-university , Brooklyn , United-kingdom , London , City-of , Belgium , American , Saar-gill , Alexis-sandler , Lucy-williams

Hemogenyx Pharmaceuticals PLC Announces CDX Antibody Update

Hemogenyx Pharmaceuticals PLC Announces CDX Antibody Update
LONDON, UK / ACCESSWIRE / April 1, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to issue an update on negotiations regarding the future development of its leading product candidate CDX bispecific antibody ( CDX ) for the treatment of acute myeloid leukemia ( AML ).
On 13 January 2021, the Company announced the completion of development of CDX with a global pharmaceutical company ( GlobalCo ). With the development phase of the agreement completed, GlobalCo or the Company may exercise an option to license the other party s intellectual property necessary to exploit the CDX antibody on an exclusive worldwide basis. ....

New-york , United-states , United-kingdom , London , City-of , Peter-redmond , Lucy-williams , Charles-goodfellow , Vladislav-sandler , Vadim-alexandre , Duncan-vasey , Matthew-johnson